Levocetirizine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Levocetirizine: From Allergic Rhinitis to Rheumatoid Arthritis
One-Sentence Summary
Levocetirizine is an H1-antihistamine originally used to treat allergic rhinitis, vasomotor rhinitis and idiopathic urticaria. The TxGNN model predicts it may be effective for rheumatoid arthritis, but there are currently 0 clinical trials and 0 publications supporting this specific prediction, so it rests on computational prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, idiopathic urticaria (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, levocetirizine is a selective H1-receptor antagonist (the active R-enantiomer of cetirizine). It is established for allergic and histamine-driven conditions of the nose and skin.
A possible link to rheumatoid arthritis is that histamine and mast cells may contribute to inflammation in synovial tissue. This idea is plausible but unvalidated. The high TxGNN score is a graph-based computational prediction only. Because the original mechanism data is missing, this link cannot be cross-checked.
Most other top-ranked predictions are rare genetic skeletal or developmental disorders (for example brachydactyly-syndactyly syndrome, acromesomelic dysplasia and brachyolmia). These have no plausible link to H1 antagonism and probably reflect knowledge-graph connectivity rather than real pharmacology. They are therefore not pursued.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for rheumatoid arthritis.
For reference, the literature retrieved for the lower-ranked "common cold" prediction is indirect or off-topic and provides no efficacy evidence:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15516152 | 2004 | Review | Drugs | Causes, management and treatment options for chronic urticaria |
| 24260733 | 2013 | Case report | Asia Pacific Allergy | Levocetirizine-induced fixed drug eruption with cross-reaction to other piperazine derivatives |
| 36709387 | 2023 | Analytical method (HPLC) | Scientific Reports | Green HPLC-UV method to measure a four-drug cold/COVID-19 symptom mixture containing levocetirizine |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14939P | ALLERZAL F.C. TABLET 5MG | Film-coated tablet | Not stated in the licence record |
| SIN16028P | XYZAL FILM-COATED TABLET 5 MG | Film-coated tablet | Not stated in the licence record |
| SIN16480P | STADELTINE FILM-COATED TABLET 5MG | Film-coated tablet | Not stated in the licence record |
| SIN16312P | ALERINIT FILM-COATED TABLET 5MG | Film-coated tablet | Not stated in the licence record |
| SIN12084P | Zyr-NEX TABLET 5 mg | Film-coated tablet | Not stated in the licence record |
A sixth licence (SIN14505P, Levozine F.C. Tablet 5mg) is also valid. All six are single-ingredient oral products and none has been cancelled.
Safety Considerations
- Contraindications (knowledge-graph associations, not label text): kidney disease, pyoureter, chronic kidney disease, chronic renal failure syndrome and end-stage renal failure. Levocetirizine is cleared by the kidneys, so renal impairment needs particular attention.
- Drug Interactions: 100 interactions were identified; the 20 reviewed are mostly Moderate, with one Minor (hyaluronidase). The main concern is additive central nervous system (CNS) depression with sedating agents:
- Opioids and related drugs: morphine (including liposomal), fentanyl, dihydrocodeine, opium, loperamide, difenoxin and diphenoxylate
- Cannabinoids: dronabinol and nabilone
- Other sedating agents: ethanol, promethazine and chlorpheniramine
- Others: bupropion, metoclopramide, sibutramine, histamine, and radioiodine (I-123 and I-131)
For warnings and contraindications from the label, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for rheumatoid arthritis scores highly (99.73%) but has no supporting clinical trials or literature (L5). The mechanistic link is speculative, and the original mechanism data and package insert safety information are missing. Evidence does not currently justify further development.
To proceed, the following is needed:
- Mechanism of action data for levocetirizine (for example from DrugBank)
- The HSA package insert (warnings, contraindications and approved indications) for safety screening
- A systematic literature search on antihistamines and H1/mast-cell involvement in rheumatoid arthritis
- Preclinical or exploratory evidence (for example synovial histamine signalling) to raise the evidence level above L5
- Dosing and renal-safety considerations for any new use, given the kidney-related contraindication associations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.